{"id":451,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"cagrilintide-amylin-analog-phase-2-evidence","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/es\/cagrilintide-amylin-analog-phase-2-evidence\/","title":{"rendered":"Cagrilintide como an\u00e1logo de amilina de acci\u00f3n prolongada: lectura de la evidencia de fase 2"},"content":{"rendered":"
Cagrilintide es un an\u00e1logo de amilina de acci\u00f3n prolongada desarrollado para un estudio semanal. Pertenece a una categor\u00eda de se\u00f1alizaci\u00f3n diferente a la de los agonistas del receptor GLP-1, aunque programas cl\u00ednicos posteriores han evaluado la cagrilintida junto con la semaglutida.<\/p>
Conclusiones clave<\/h2>
Cagrilintide es un an\u00e1logo de amilina; La semaglutida es un agonista del receptor GLP-1.<\/li>
La evidencia de la fase de agente \u00fanico 2 debe distinguirse de los ensayos combinados posteriores de CagriSema.<\/li>
Seg\u00fan la informaci\u00f3n revisada de FDA, la cagrilintida no es un componente de un medicamento aprobado por FDA.<\/li><\/ul><\/div><\/div>Ilustraci\u00f3n de laboratorio original de la investigaci\u00f3n de receptores de p\u00e9ptidos; Las v\u00edas son conceptuales y no contienen datos de ensayos.<\/figcaption><\/figure>
Por qu\u00e9 la amilina es una v\u00eda de investigaci\u00f3n distinta<\/h2>
La amilina se secreta conjuntamente con la insulina y participa en la se\u00f1alizaci\u00f3n relacionada con los nutrientes. Cagrilintide fue dise\u00f1ado para una exposici\u00f3n prolongada en relaci\u00f3n con la amilina nativa. La farmacolog\u00eda de su receptor y su dise\u00f1o molecular no son intercambiables con GLP-1, GIP o el agonismo del receptor de glucag\u00f3n.<\/p>
Qu\u00e9 aporta el ensayo en fase 2<\/h2>
El ensayo de fase aleatorizada 2 compar\u00f3 m\u00faltiples grupos de dosis de cagrilintida con placebo y un comparador activo en adultos con sobrepeso u obesidad. Evalu\u00f3 el cambio en el peso corporal y la seguridad durante el per\u00edodo de estudio. El documento apoyaba el desarrollo continuo, pero no convert\u00eda a la cagrilintida en un medicamento aprobado.<\/p>
Al resumir el ensayo, los detalles \u00fatiles son la poblaci\u00f3n, la aleatorizaci\u00f3n, el comparador, la duraci\u00f3n, el criterio de valoraci\u00f3n principal y el patr\u00f3n de eventos adversos. Copiar un porcentaje m\u00e1ximo sin esos calificadores no es una revisi\u00f3n de evidencia adecuada.<\/p>
clase de mol\u00e9cula<\/strong>An\u00e1logo de amilina de acci\u00f3n prolongada<\/span><\/div>
Tipo de evidencia<\/strong>Ensayo en humanos 2 en fase aleatorizada<\/span><\/div>
L\u00edmite de desarrollo<\/strong>En investigaci\u00f3n; no es equivalente a los productos de semaglutida aprobados<\/span><\/div><\/div><\/div>
Agente \u00fanico no es lo mismo que CagriSema<\/h2>
CagriSema se refiere a la coadministraci\u00f3n de cagrilintida y semaglutida en programas cl\u00ednicos espec\u00edficos. Los resultados de esa combinaci\u00f3n no pueden presentarse como resultados de cagrilintida sola, y ninguno de los conjuntos de datos valida una mezcla suministrada de forma independiente a menos que se establezca la equivalencia y la calidad del producto.<\/p>","protected":false},"excerpt":{"rendered":"
Una gu\u00eda basada en fuentes sobre la farmacolog\u00eda del receptor de amilina de cagrilintida, el dise\u00f1o del ensayo de fase 2 y el l\u00edmite entre la evidencia de agente \u00fanico y combinaci\u00f3n.<\/p>","protected":false},"author":1,"featured_media":621,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"320","pim_article_type":"Clinical evidence review","pim_evidence_level":"Randomized phase 2 human trial; investigational single-agent context","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Once-weekly cagrilintide in people with overweight and obesity \u2014 phase 2 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34798060\/\",\"note\":\"Primary randomized phase 2 record; PMID 34798060.\"},{\"title\":\"FDA information on cagrilintide and other unapproved GLP-1-related products\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Current regulatory-status boundary.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-451","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\n
Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence - NHD<\/title>\n<meta name=\"description\" content=\"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/es\/cagrilintide-amylin-analog-phase-2-evidence\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence\" \/>\n<meta property=\"og:description\" content=\"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/es\/cagrilintide-amylin-analog-phase-2-evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\"},\"wordCount\":284,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\",\"name\":\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/es\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cagrilintide como an\u00e1logo de amilina de acci\u00f3n prolongada: lectura de la fase Evidencia 2 - NHD","description":"Una gu\u00eda basada en fuentes sobre la farmacolog\u00eda del receptor de amilina de cagrilintida, el dise\u00f1o del ensayo de fase 2 y el l\u00edmite entre la evidencia de agente \u00fanico y combinaci\u00f3n.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/es\/cagrilintide-amylin-analog-phase-2-evidence\/","og_locale":"es_ES","og_type":"article","og_title":"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence","og_description":"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.","og_url":"https:\/\/nhdbio.com\/es\/cagrilintide-amylin-analog-phase-2-evidence\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"},"wordCount":284,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/","url":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/","name":"Cagrilintide como an\u00e1logo de amilina de acci\u00f3n prolongada: lectura de la fase Evidencia 2 - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Una gu\u00eda basada en fuentes sobre la farmacolog\u00eda del receptor de amilina de cagrilintida, el dise\u00f1o del ensayo de fase 2 y el l\u00edmite entre la evidencia de agente \u00fanico y combinaci\u00f3n.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Materias primas pept\u00eddicas y s\u00edntesis personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipo t\u00e9cnico de NHD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"El equipo t\u00e9cnico de NHD mantiene documentaci\u00f3n del cat\u00e1logo de uso de investigaci\u00f3n y res\u00famenes de evidencia. Los art\u00edculos revisados \u200b\u200benlazan con art\u00edculos revisados \u200b\u200bpor pares, registros de ensayos y registros regulatorios, conservan hallazgos nulos y limitaciones de estudios, y distinguen las intervenciones publicadas de los materiales del cat\u00e1logo. Se puede utilizar dibujo asistido por AI para la estructura; los enlaces de fuentes y los l\u00edmites de las pruebas permanecen visibles. Este trabajo no es una revisi\u00f3n por pares independiente ni un consejo m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/es\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/comments?post=451"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/451\/revisions"}],"predecessor-version":[{"id":520,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/451\/revisions\/520"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media\/621"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media?parent=451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/categories?post=451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/tags?post=451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Investigador](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png\")